|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NINDS, NCCIH, NIDA, NIDCR, NINR
|
The Interagency Pain Research Coordination Committee is an Affordable Care Act-mandated committee to coordinate pain research activities across the government.
|
|
Interagency Precision Medicine Initiative Working Group (IPMI WG)
|
Committee, Work group, Advisory group, or Task Force
|
FDA, OS
|
OD/OSP
|
The IPMI WG coordinates activities across the Federal government to enhance innovation in precision medicine, with the ultimate goal of moving the United States into an era where medical care can be more precisely tailored to each patient and the best outcomes can be achieved for all.
|
|
Interagency Select Agent Review Group (ISARG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
NIAID, OD/OM/OB, OD/OSP
|
The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the NIH-OD and BARDA, advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed.
|
|
Interagency Task Force on Military and Veterans Mental Health (ITF)
|
Committee, Work group, Advisory group, or Task Force
|
ACL, OS, SAMHSA
|
NIMH
|
Executive Order 13625, Improving Access to Mental Health Services for Veterans, Service Members, and Military Families, was released on August 31, 2012, and directed the Departments of Defense (DoD), Veterans Affairs (VA), and Health and Human Services (HHS) to ensure that Veterans, Service Members, and their families have access to needed mental health services and support. The Executive Order also established the Interagency Task Force on Military and Veterans Mental Health (ITF) and directed it to provide an annual review of agency actions, to define specific goals and metrics to aid in measuring progress, and make additional recommendations as appropriate to the President to improve mental health and substance use disorder treatment services for Veterans, Service Members, and their families. The ITF, co-chaired by the DoD Assistant Secretary for Health Affairs, the VA Under Secretary for Health, and the HHS Administrator for the Substance Abuse and Mental Health Services Administration, tracks and reports progress in executing all activities resulting from recommendations made pursuant to the Executive Order.
|
|
Interagency Workgroup on Technology to Facilitate Aging in Place
|
Research Initiative
|
ACL, CMS, FDA
|
NIA, NCI, NHLBI, NIBIB, NINDS, NINR
|
The purpose of this Trans-NIH/Inter-Agency group is to develop new platforms for everyday life technology that will enhance the common goals of multiple NIH institutes and other federal government agencies by improving the capability to rapidly conduct peer-reviewed technology research to facilitate aging in place, with a special emphasis on people from underrepresented groups. A platform is a group of technologies that are used as a base upon which other applications, processes or technologies are developed.
|
|
Interagency Working Group in the Glycosciences
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NIGMS, NCI, NICHD, NIDCR, NIDDK
|
This group meets annually to identify synergies, discuss progress on the development of national standards for carbohydrates, and exchange information on the glycosciences being pursued at each agency
|
|
Interagency Working Group on Open Science
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, CDC, FDA, OS
|
OD/OSP, OD/OER
|
The Interagency Working Group on Open Science (IWGOS) was established in October 2016 to advance Federal efforts to support open science by increasing access to and use of the results of Federally funded research and development, including but not limited to scholarly publications and digital data. Among its responsibilities, the IWGOS aims to improve implementation of policies to increase access to the results of Federally funded scientific research as described in a February 2013 memorandum from the Director of the Office of Science and Technology Policy (OSTP) and to identify additional steps that Federal departments and agencies can take to enhance the preservation, discoverability, accessibility, quality, and utility of the outputs of Federally funded scientific research.
|
|
International Cancer Control Partnership
|
Other
|
CDC
|
NCI
|
The National Cancer Institute and the Union for International Cancer Control convened global partners including the Centers for Disease Control and Prevention (CDC) to cooperate in assisting countries to develop and implement quality cancer plans linked to Non-communicable Disease (NCD) control. This International Cancer Control Partnership, ICCP, believes that prioritizing cancer is critical to reaching the “25x25” goal. ICCP partners will assist countries by: (1) Creating a searchable database of current cancer control plans from around the globe; (2) Performing analysis of gaps and highlighting priority areas for inclusion in plans; (3) Training appropriate personnel to develop plans with targets and evaluation strategies; (4) Providing planners with relevant existing materials and tools; and (5) Offering technical assistance. ICCP partners will use their collective state, country, and regional-level planning experience to guide plan development and implementation and will ensure planners utilize effective, evidence-based strategies to help meet the global NCD targets.
|
|
International Neonatal Consortium
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NICHD
|
INC accelerates the development of safe and effective therapies for neonates. The consortium engages the global neonatal community – families, neonatal nurses, academic scientists, regulators, pharmaceutical investigators, advocacy organizations, and funders – to focus on the needs of the neonate. Through teams that share data, knowledge, and expertise, INC will advance medical innovation and regulatory science for this underserved population.
|
|
International Rare Diseases Research Consortium (IRDiRC) Funders'' Committee
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NICHD, NCATS, NCI, NEI, NHGRI, NIAMS, NINDS
|
The International Rare Diseases Research Consortium (IRDiRC) teams up researchers and organizations investing in rare diseases research in order to achieve two main objectives by the year 2020, namely to deliver 200 new therapies for rare diseases and means to diagnose most rare diseases. A number of grand challenges are being addressed through collaborative actions to reach these 2020 goals such as establishing and providing access to harmonized data and samples, performing the molecular and clinical characterization of rare diseases, boosting translational, preclinical and clinical research, and streamlining ethical and regulatory procedures.
|